Descriptive analysis of mortality from bronchus and lung cancer in Chile: An epidemiological overview of 20 years (2002-2022)
DOI:
https://doi.org/10.52611/confluencia.2026.1453Keywords:
Lung cancer, Bronchial neoplasms, Mortality, Epidemiology, ChileAbstract
Introduction: Bronchus and lung cancer is a malignant neoplasm originating from the bronchial epithelium or pulmonary parenchyma. Objective: To establish the mortality rate from bronchus and lung cancer in Chile between 2002 and 2022. Methods: A cross-sectional, observational, descriptive, and retrospective study was conducted. Deaths from bronchus and lung cancer (ICD-10 code C34) recorded in Chile from 2002 to 2022 were analyzed, based on official data from the Department of Statistics and Health Information. The variables considered were: cause of death, sex, age, and region. Mortality rate were calculated using population projections from the National Institute of Statistics. Result: A total of 59.720 deaths from lung cancer were recorded, with an average mortality rate of 15,39 per 100.000 inhabitants. Mortality was higher in men (19,02) than in women (11,79). The highest mortality rate was observed in older adults (65 years of age or older), reaching 78,67 per 100.000. Regionally, Antofagasta had the highest mortality rate (26,45), while Ñuble and La Araucanía had the lowest. Discussion: The increasing mortality trend reflects the persistence of tobacco use, population aging, and regional environmental exposures. The low five-year survival rate and delayed diagnosis emphasize the urgent need to implement early detection programs. Conclusion: This study highlights a high and rising burden of lung cancer mortality in Chile. Integrated public health policies are needed to improve prevention, early diagnosis, and timely access to treatment.
References
1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin [Internet]. 2023 [citada el 12 de julio 2025];73(1):17-48. Disponible en: http://dx.doi.org/10.3322/caac.21763
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin [Internet]. 2021 [citado el 12 de julio 2025];71(3):209-49. Disponible en: http://dx.doi.org/10.3322/caac.21660
3. Leiter A, Veluswamy RR, Wisnivesky JP. The global burden of lung cancer: current status and future trends. Nat Rev Clin Oncol [Internet]. 2023 [citado el 12 de julio 2025];20(9):624-39. Disponible en: http://dx.doi.org/10.1038/s41571-023-00798-3
4. Islami F, Marlow EC, Thomson B, McCullough ML, Rumgay H, Gapstur SM, et al. Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, 2019. CA Cancer J Clin [Internet]. 2024 [citado el 12 de julio 2025];74(5):405-32. Disponible en: http://dx.doi.org/10.3322/caac.21858
5. Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2018. Bethesda (MD): National Cancer Institute; 2021 [citado el 12 de julio 2025]. Disponible en: https://seer.cancer.gov/csr/1975_2018/
6. Kim J, Lee H, Huang BW. Lung Cancer: Diagnosis, Treatment Principles, and Screening. Am Fam Physician. 2022 [citado el 12 de julio 2025];105(5):487-94. Disponible en: https://pubmed.ncbi.nlm.nih.gov/35559635/
7. Reck M, Remon J, Hellmann MD. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. J Clin Oncol [Internet]. 2022 [citado el 12 de julio 2025];40(11):586-97. Disponible en: http://dx.doi.org/10.1200/JCO.21.01497
8. Lindeman NI, Cagle PT, Aisner DL, Arcila ME, Beasley MB, Bernicker EH, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med [Internet]. 2018 [citado el 12 de julio 2025];142(3):321-46. Disponible en: http://dx.doi.org/10.5858/arpa.2017-0388-CP
9. Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu Y-L, et al. Lung cancer: current therapies and new targeted treatments. Lancet [Internet]. 2017 [citado el 12 de julio 2025];389(10066):299-311. Disponible en: http://dx.doi.org/10.1016/S0140-6736(16)30958-8
10. Araghi M, Mannani R, Heidarnejad Maleki A, Hamidi A, Rostami S, Safa SH, et al. Recent advances in non-small cell lung cancer targeted therapy; an update review. Cancer Cell Int [Internet]. 2023 [citado el 12 de julio 2025];23(1):162. Disponible en: http://dx.doi.org/10.1186/s12935-023-02990-y
11. Mino-Kenudson M, Schalper K, Cooper W, Dacic S, Hirsch FR, Jain D, et al. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol [Internet]. 2022 [citado el 12 de julio 2025];17(12):1335-54. Disponible en: http://dx.doi.org/10.1016/j.jtho.2022.09.109
12. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature [Internet]. 2018 [citado el 12 de julio 2025];553(7689):446-54. Disponible en: http://dx.doi.org/10.1038/nature25183
13. Shukla AA, Podder S, Chaudry SR, Benn BS, Kurman JS. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. AIMS Med Sci [Internet]. 2022 [citado el 12 de julio 2025];9(2):348-61. Disponible en: http://dx.doi.org/10.3934/medsci.2022016
14. Lahiri A, Maji A, Potdar PD, Singh N, Parikh P, Bisht B, et al. Lung cancer immunotherapy: progress, pitfalls, and promises. Mol Cancer [Internet]. 2023 [citado el 12 de julio 2025];22(1):40. Disponible en: http://dx.doi.org/10.1186/s12943-023-01740-y
15. Mamdani H, Matosevic S, Khalid AB, Durm G, Jalal SI. Immunotherapy in Lung Cancer: Current Landscape and Future Directions. Front Immunol [Internet]. 2022 [citado el 12 de julio 2025];13:823618. Disponible en: http://dx.doi.org/10.3389/fimmu.2022.823618
16. Wang Z, Cai G, Zhu J, Wang J, Zhang Y. Treatment of advanced‑stage non‑small cell lung cancer: Current progress and a glimpse into the future (Review). Mol Clin Oncol [Internet]. 2025 [citado el 12 de julio 2025];22(5):42. Disponible en: http://dx.doi.org/10.3892/mco.2025.2837
17. Liu SM, Zheng MM, Pan Y, Liu SY, Li Y, Wu YL. Emerging evidence and treatment paradigm of non-small cell lung cancer. J Hematol Oncol [Internet]. 2023 [citado el 12 de julio 2025];16(1):40. Disponible en: http://dx.doi.org/10.1186/s13045-023-01436-2
18. Turner MC, Andersen ZJ, Baccarelli A, Diver WR, Gapstur SM, Pope CA 3rd, et al. Outdoor air pollution and cancer: An overview of the current evidence and public health recommendations. CA Cancer J Clin [Internet]. 2020 [citado el 12 de julio 2025];70(6):460-79. Disponible en: http://dx.doi.org/10.3322/caac.21632
19. Berg CD, Schiller JH, Boffetta P, Cai J, Connolly C, Kerpel-Fronius A, et al. Air pollution and Lung Cancer: A review by International Association for the Study of Lung Cancer Early Detection and Screening Committee. J Thorac Oncol [Internet]. 2023 [citado el 12 de julio 2025];18(10):1277-89. Disponible en: http://dx.doi.org/10.1016/j.jtho.2023.05.024
20. Bade BC, Dela Cruz CS. Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med [Internet]. 2020 [citado el 12 de julio 2025];41(1):1-24. Disponible en: http://dx.doi.org/10.1016/j.ccm.2019.10.001
21. de Koning HJ, van der Aalst CM, de Jong PA, Scholten ET, Nackaerts K, Heuvelmans MA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med [Internet]. 2020 [citado el 12 de julio 2025];382(6):503-13. Disponible en: http://dx.doi.org/10.1056/NEJMoa1911793
22. Abu Qubo A, Numan J, Snijder J, Padilla M, Austin JHM, Capaccione KM, et al. Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges. Breathe (Sheff) [Internet]. 2022 [citado el 12 de julio 2025];18(4):220147. Disponible en: http://dx.doi.org/10.1183/20734735.0147-2022
23. Knapp BJ, Devarakonda S, Govindan R. Bone metastases in non-small cell lung cancer: a narrative review. J Thorac Dis [Internet]. 2022 [citado el 12 de julio 2025];14(5):1696-712. Disponible en: http://dx.doi.org/10.21037/jtd-21-1502
24. Haryati H, Rahmawaty D, Wanahari TA. Implementing Palliative and End-of-Life Care in Lung Cancer: When to Start? Jurnal Respirasi [Internet]. 2023 [citado el 12 de julio 2025];9(1):64-71. Disponible en: http://dx.doi.org/10.20473/jr.v9-i.1.2023.64-71
25. World Health Organization. WHO global report on trends in prevalence of tobacco use 2000-2025, fourth edition. Ginebra, Suiza: WHO; 2021 [citado el 12 de julio 2025]. Disponible en: https://www.who.int/publications/i/item/9789240039322
26. Departamento de Estadísticas e Información de Salud, Chile. Base de datos de mortalidad por causa específica en Chile 2012–2022 [Internet]. Santiago: MINSAL; 2023 [citado el 12 de julio 2025]. Disponible en: https://deis.minsal.cl
27. Organización Panamericana de la Salud. Clasificación Estadística Internacional de Enfermedades y Problemas Relacionados con la Salud Décima Revisión [Internet]. Washington: OPS; 1995 [citado el 12 de julio 2025]. Disponible en: https://ais.paho.org/classifications/chapters/pdf/volume1.pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Revista Confluencia

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



